MedTrace Logo

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

NCT03553615 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-12-02

No results posted yet for this study

Summary

This pilot trial studies how well a novel oral therapeutic agent performs to treat patients with atopic dermatitis, particularly facial dermatitis.

Conditions

Interventions

DRUG

Ivermectin Pill

oral anti-parasitic agent taken as a weekly dose for four weeks

Sponsors & Collaborators

Principal Investigators

  • Kavita Sarin, MD, PhD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2030-12-01
Primary Completion
2030-12-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03553615 on ClinicalTrials.gov